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10Background: Cardiovascular risk assessment in the clinical
practice is mostly based on risk charts, such as
Framingham risk score and Systemic Coronary Risk
Estimation (SCORE). These enable clinicians to estimate the
impact of cardiovascular risk factors and assess individual
cardiovascular risk profile. Risk charts, however, do not
take into account subclinical organ damage, which exerts
independent influence on risk and may amplify the
estimated risk profile. Inclusion of organ damage markers
in the assessment may thus contribute to improve this
process.
Objective: Our aim was to evaluate the influence of
implementation of SCORE charts with widely available
indexes of organ damage, with the purpose to ameliorate
individual risk assessment.
Methodology: We searched www.Pubmed.gov for
evidence about the predictive value of left ventricular
hypertrophy (LVH), estimated glomerular filtration rate
(eGFR), microalbuminuria (MAU) and metabolic syndrome
on different risk profiles estimated by SCORE.
Interventional and observational trials including at least
200 patients and published after 2000 were selected.
Results: The presence of organ damage as well as the
number of abnormal parameters indicating organ damage
is associated with increased cardiovascular risk,
independently of SCORE. In the area of high risk, the
impact of different markers of organ damage is
heterogeneous. Combined risk models of SCORE and
subclinical organ damage have major impact on risk
stratification and may impact on recommendation in
primary prevention in all SCORE categories.
Conclusion: Available evidence suggests a tangible clinical
advantage of adding the evaluation of simple organ
damage markers to risk charts in cardiovascular risk
prediction.
Keywords: cardiovascular risk, estimated glomerular
filtration rate, left ventricular hypertrophy, metabolic
syndrome, microalbuminuria, prevention, SCORE, target
organ damage
Abbreviations: ACR, albumin/creatinine ratio; CKD,
chronic kidney disease; CKD-EPI, chronic kidney disease
epidemiology collaboration; CVD, cardiovascular disease;Copyright © Lippincott Williams & Wilkins. Unaut
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density lipoprotein; LVH, left ventricular hypertrophy;
MAU, microalbuminuria; MDRD, modification of diet in
renal disease; MetS, metabolic syndrome; MI, myocardial
infarction; PRISMA, preferred reporting items for
systematic review and meta-analysis; SCORE, Systemic
Coronary Risk Estimation; TOD, target organ damage;
UACR, urinary albumin/creatinine ratioINTRODUCTIONC
ardiovascular disease (CVD) is the leading cause of
death worldwide, leading to 4.3 million of deaths
per year in Europe [1]. Particularly, in Italy, CVD
accounts for 44% of total deaths (Centro Nazionale di
Epidemiologia, Sorveglianza e Promozione della Salute).
Over the last years, different algorithms concerning
cardiovascular risk stratification have been developed to
prospectively estimate the risk of cardiovascular mortality.
Such scores are based mainly on the presence or the
absence of traditional modifiable and nonmodifiable
cardiovascular risk factors. Framingham Risk Score and
Systemic Coronary Risk Estimation (SCORE) projects have
been thoroughly validated and largely used in clinical
practice. However, despite the availability of a large
number of scores, it is still hard to identify powerfulhorized reproduction of this article is prohibited.
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cardiovascular risk. The lack of any clue on subclinical
organ damage in the available risk charts exemplifies the
failure to intercept patients with significant cardiovascular
risk. As a result, treatment strategies aimed at preventing
CVD are not always tailored on the real individual risk
profile.
Although preventive strategies for high-risk patients are
well defined by current guidelines, the challenge of CVD
risk prediction is mostly focused on those patients defined
at intermediate risk. This category of patients could be
better addressed at the individual clinical level by a more
accurate risk stratification including cost-effective, second-
level tests that have recently shown a high predictive value
for cardiovascular events [2,3]. As suggested by 2007
European Society of Hypertension/European Society of
Cardiology (ESH/ESC) hypertension guidelines, the evalu-
ation of global cardiovascular risk should take into account
subclinical target organ damage beyond traditional cardio-
vascular risk factors [3]. However, the impact of organ
damage among different risk categories is still not clear.
Also, the identification of metabolic syndrome (MetS), an
easy and practical clinical task, has been advocated in the
guidelines as a potential cardiovascular risk predictor to be
integrated with traditional charts [3]. However, its discrete
influence on estimation of global risk has not been defined.
Only few studies have investigated whether the assessment
of cardiovascular risk by risk charts can be ameliorated by
adding target organ damage (TOD) and MetS.
According to available literature, we attempted to crit-
ically discuss current evidence supporting the additional
predictive value of left ventricular hypertrophy (LVH),
reduction of estimated glomerular filtration rate (eGFR)
and microalbuminuria (MAU) as TOD markers, and MetS
beyond the SCORE project. The aim of this work is to
propose an updated and documented viewpoint on the
need to modify SCORE charts to better define the individual
cardiovascular risk on a large-scale population based on the
addition of simple and low-cost parameters, easily and
widely available in the routine clinical setting.
SEARCHMETHODOLOGY
On the basis of the vast amount of evidence existing in
literature, we selected the following markers of organ
damage for our search: LVH, eGFR, MAU. We also searched
for MetS. All articles in English available until March 2011 on
www.Pubmed.com by introducing the terms ‘left ventric-
ular hypertrophy/estimated glomerular filtration rate/
microalbuminuria/metabolic syndrome and cardiovascular
risk’, ‘left ventricular hypertrophy/estimated glomerular
filtration rate/microalbuminuria/metabolic syndrome and
cardiovascular events’, ‘left ventricular hypertrophy/esti-
mated glomerular filtration rate/microalbuminuria/meta-
bolic syndrome and risk score’ were screened for our
search. Out of the results retrieved, we eliminated dupli-
cates and substudies, then we selected interventional and
observational studies electing those with population of at
least 200 patients, particularly those studies published after
2000 and meta-analyses most representative for our pur-
pose. Our decisional process actually adhered to all theCopyright © Lippincott Williams & Wilkins. Unauth
Journal of Hypertensionsteps of the four-phase flow diagram published by
Preferred Reporting Items for Systematic reviews and
Meta-analysis (PRISMA) [4] in 2009. Most of the studies
reported used hazard ratio and relative risk as index of
the association between TOD and outcomes. Our analysis
largely reflects the checklist and methodology recently
proposed by PRISMA.
THE SYSTEMIC CORONARY RISK
ESTIMATION PROJECT
SCORE is a widely used risk chart for cardiovascular risk
stratification in healthy individuals. It is based on risk
functions derived from the analysis of 12 European cohort
studies and calculates 10-year risk of cardiovascular death
based on age, sex, SBP, cholesterol and smoking. SCORE
also provides risk charts calibrated to each geographic
region in Europe. Two parallel SCORE models have been
developed: one based on total cholesterol and the other on
total cholesterol/high-density lipoprotein (HDL) choles-
terol ratio. The risk estimations are displayed graphically
in simple risk charts [5].
LEFT VENTRICULAR HYPERTROPHY
Data about the importance of the presence of LVH as well as
of other markers of TOD in hypertensive patients appear to
be relevant because hypertension is a very common risk
condition in the general population. The analysis of this
subgroup of patients could indeed represent a gateway for
the analysis of TOD also in other population subgroups.
Electrocardiography is commonly used in the routine
assessment of individuals with high blood pressure as well
as practically in all other groups of individuals carrying
cardiovascular risk factors. Although sensitivity is low, LVH
detected by the Sokolow–Lyons index (SV1þRV5–6
>38mm) or by the Cornell voltage QRS duration product
(>2440 mm/ms) is an independent predictor of cardiovas-
cular events [3,5–16]. LVH has been shown to be predictive
of major cardiovascular events (including stroke) and all-
cause mortality, independent of blood pressure, and across
all racial groups that have been studied. In the Framingham
Study, for every 50 g/m2 LVH increase, there was a relative
risk (RR) of death of 1.73 [95% confidence interval (CI)
1.19–2.52] independent of blood pressure level [17]. In the
African–American population enrolled in the ARIC study,
LVH conferred an increased risk for CVD events [nonfatal
myocardial infarction (MI), cardiac death, coronary
revascularization, and stroke] even after adjusting for other
risk factors with a hazard ratio of 1.88 in men and 1.92 in
women. Among American Indians enrolled in the Strong
Heart Study (64% women, mean age 58 years), the LVH
prevalence on echocardiography was 9.5% and conferred a
seven-fold increase in cardiovascular mortality and a four-
fold increase in all-cause mortality [17]. Of note, in hyper-
tensive individuals, left ventricular mass showed a linear
correlation with cardiovascular risk, which extended even
below the conventional cut-off levels for LVH [11]. Specifi-
cally, regarding the ECG-detected LVH, the Framingham
cohort individuals in the highest quartile of ECG–LVH
displayed a three-fold increase in risk of CVD as comparedorized reproduction of this article is prohibited.
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derived Perugia score for definition of LVH carried the
highest population-attributable risk for cardiovascular mor-
bidity and mortality compared with classic methods for
detection of LVH [9]. Moreover several studies have shown
that reduction of ECG–LVH is significantly associated with
reduced cardiovascular risk [8,18,19]. Recently, a LIFE (Los-
artan Intervention for Endpoint reduction in Hypertension)
substudy showed that in individuals with low in-treatment
ECG–LVH, the rate of fatal and nonfatal cardiovascular
events was strongly reduced, regardless of blood pressure
reduction [20]. In fact, after controlling for possible con-
founders in Cox regression models, the composite cardio-
vascular end point (cardiovascular death, fatal or nonfatal
MI, and fatal or nonfatal stroke) was 14% lower for every
decrease in 1 SD (1050 mm ms) in Cornell product and 17%
lower for every decrease in 1 SD (10.5 mm) in Sokolow–
Lyon voltage. Further observations using the more sensitive
echocardiographic technique have shown that patients
who achieve LVH regression during follow-up are much
less likely to experience morbid events as compared with
those with persistence of LVH [21,22]. These observations
have been reinforced by other studies and by the results
of the echocardiographic substudy of LIFE in which a
reduction of 25 g/m2 in left ventricular mass (corresponding
to 1 SD of baseline value) was associated with a reduction of
22% in the primary composite end point during 4.6 years of
follow-up, even after adjusting for possible confounders
[23].
In a recent meta-analysis that involved five prospective
studies (2449 individuals with a follow-up duration ranging
from 3 to 9 years), it has been shown that echocardio-
graphic LVH regression in hypertension is associated with
reduced risk of future cardiovascular events. The overall
adjusted hazard ratio was 0.54 for LVH regression/persist-
ent normal left ventricular mass vs. LVH persistence/LVH
development [24].
It should also be mentioned that without ultrasound
investigations for LVH and vascular thickening or plaques,
a significant portion of hypertensive individuals, especially
men older than 50 years, may be mistakenly classified as at
low or moderate added risk, whereas the presence of
cardiac or vascular damage classifies them within a higher
risk group [3,25]. Despite this, it is still necessary to perform
new specific studies that would address the definition of the
usefulness of ECG-LVH in reclassifying the added relative
risk of individuals through specific Bayesian statistic
methods such as receiving–operating curves. In our
opinion, an electrocardiographic screening for LVH could
be the best strategy in a primary prevention setting, given
also the high cost-effectiveness of echocardiography [25].
ESTIMATED GLOMERULAR FILTRATION
RATE
The US National Kidney Foundation has provided guide-
lines for the chronic kidney disease (CKD) evaluation,
classification and stratification. Definitions of stages 1–5
of CKD correspond to eGFR levels of at least 90, 60–89, 30–
59, 15–29 and less than 15ml/min per 1.73 m2. Stage 3
(eGFR <60ml/min per 1.73 m2) is generally the stage atCopyright © Lippincott Williams & Wilkins. Unaut
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is considered as the cut-off point for moderate–severe CKD
[26].
Reduced eGFR is associated with high prevalence of
CVD risk factors, CVD surrogates and clinical CVD [27] and
has been repeatedly found to be an independent risk factor
for CVD outcome in high-risk populations [28–33] and in
hypertensive patients [34–36]. Shara et al. [33] showed in a
large cohort with high prevalence of diabetes that, com-
pared with individuals whose eGFR was at least 90ml/min
per 1.73 m2 at baseline, those with eGFR less than 30, 30–59
and 60–89ml/min per 1.73 m2 using either modification of
diet in renal disease (MDRD) and Cockcroft–Gault
equation, had increased risk of incident CVD.
In 2006, a pooled analysis of four community-based
studies involving 26147 individuals showed that the pres-
ence of stage 3 of CKD was an independent risk factor for
cardiac events, stroke and death (hazard ratio 1.26; CI 95%
1.16–1.35; P< 00001) [37]. Similar results were reinforced in
2007 by a meta-analysis of six previous reports involving a
total of 4720 incident coronary heart disease cases which
yielded a combined risk ratio of 1.41 in individuals with
baseline eGFR less than 60 ml/min per 1.73 m2 compared
with those with higher values [38]. In 2010, the Chronic
Kidney Disease Prognosis Consortium published a collab-
orative meta-analysis involving 105 872 individuals from 21
general population cohorts. This meta-analysis showed that
eGFR and albuminuria were associated with all-cause
mortality and cardiovascular mortality, independently of
each other and of traditional cardiovascular risk factor. The
risk for cardiovascular mortality became significant around
eGFR 60ml/min per 1.73 m2 (hazard ratio 1.40) and even
grew for smaller value of eGFR (hazard ratio 1.99 when
eGFR 45 ml/min per 1.73 m2; hazard ratio 2.66 when eGFR
15ml/min per 1.73 m2). In addition, eGFR lower than 60ml/
min per 1.73 m2 showed a similar association with risk of
mortality across all levels of albuminuria and vice versa,
suggesting a role of multiplicative independent risk factor
for mortality [39].
A relationship between eGFR less than 60ml/min per
1.73 m2 values and the risk of cardiovascular mortality and
morbidity has been reported even in low-risk population
[40–45]. A study involving more than 1 million individuals
showed that the progressive decline of eGFR was associ-
ated with an increase in the risk of mortality. eGFR values
ranging from 45 to 59, 30 to 44, 15 to 29 and less than
15ml/min per 1.73 m2 were associated with 1.2-fold,
1.8-fold, 3.2-fold and 5.9-fold increase in mortality, when
compared with individuals with preserved renal function
(eGFR60ml/min per 1.73 m2). Similarly, the hazard ratios
for cardiovascular events progressively increased with the
impairment of glomerular filtration [41]. Interestingly, evi-
dence also suggest that even minor declines of renal func-
tion, can be associated with increased risk of cardiovascular
mortality and morbidity [46–48]. It has been calculated that
a decrease in eGFR of 5ml/min per 1.73 m2 within the 116.9
and 16.8 ml/min per 1.73 m2 range is associated with a 26%
increase in cardiovascular mortality risk [47]. Similar results
were obtained also in a cohort of healthy people [49] and in
elderly individuals [26]. The Atherosclerotic Risk in Com-
munities Study found a 16% increase cardiovascular risk forhorized reproduction of this article is prohibited.
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1.73 m2 as compared with those displaying a normal renal
function (eGFR above 90ml/min per 1.73 m2) [48].
More recently, a cohort study involving hypertensive
patients showed that eGFR less than 60ml/min per
1.73 m2 was related to the presence of CVD regardless of
cardiovascular risk profile as defined by SCORE. Interest-
ingly, the evaluation of eGFR in addition to the SCORE
increased the accuracy in identifying patients with CVD
(AUC of ROC analyses of individual probability to have total
CVD for SCORE alone was 0.66, instead for SCOREþCKD
was 0.69) [50]. Moreover, in 2010, it has been suggested that
a new equation for eGFR recently published by the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI)
could categorize more appropriately individuals with
respect to long-term cardiovascular risk compared with
MDRD study equation, suggesting improved clinical use-
fulness [51]. However, prospective studies addressing the
predictive value of eGFR beyond SCORE in clinical practice
are still lacking. This aspect is of outmost importance since a
simple and reliable index of renal function as eGFR could
increase disproportionately the accuracy of available scores
in the prediction of cardiovascular events in primary pre-
vention.
MICROALBUMINURIA
Due to its low molecular weight, albumin can be filtered
through the glomerular capillaries, then it is reabsorbed by
the proximal tubular cells till a maximal capacity. When the
system is exhausted, because of increased glomerular leak-
age low quantities of albumin can be detected in the urine,
MAU, which is defined as excretion of urinary albumin
above 20mg/min or between 30 and 300 mg/24 h or 20–
200 mg/l in spot urine collection or as urinary albumin/
creatinine ratio (UACR) above 2.5–25mg/mmol in men and
3.5–25mg/mmol in women or at least 22mg/g (men) and at
least 31mg/g (women) and less than 300 mg/mmol [52].
Excretion of urinary albumin in the MAU range can be
considered a candidate prediction biomarker for CVD risk
for several reasons. Standard CVD risk factors are associated
with MAU and this is associated with incident hypertension,
progression to a higher blood pressure category and inci-
dent diabetes [17]. In the past decade, a large body of
evidence has been published suggesting that the value of
MAU as predictor of cardiovascular events and total
mortality may be extended to diabetic and nondiabetic
individuals, hypertensive patients and general population
[52–63]. A meta-analysis of 26 cohort studies including
169 949 participants reported that after accounting for
standard CVD risk factors, there was a stepwise relationship
between albuminuria and risk of CHD. Compared with
individuals without albuminuria, macroalbuminuria was
associated with a doubling of risk (RR 2.17; 95% CI
1.87–2.52) and MAU was associated with a nearly 50%
greater risk (RR 1.47; 95% CI 1.30–1.66) of CHD [64].
Recently, a LIFE substudy showed that in hypertensive
patients with LVH fatal and nonfatal cardiovascular events
increased disproportionately across deciles of MAU,
strongly suggesting a linear relation between MAU and
raised cardiovascular risk [65]. Moreover, it has been shownCopyright © Lippincott Williams & Wilkins. Unauth
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mortality with such a relationship maintained even within
normal range of UACR [66–68]. Indeed, in the large the
Netherlands cohort of the PRevention of Renal and Vascular
End Stage Disease study, after adjustment for cardiovascular
risk factors, a two-fold increase in urinary albumin
excretion (UAE) was associated with a 29% increased risk
of death from CVD. Across the whole spectrum of UAE,
there was a continuous association between CVD and
increasing albuminuria [67]. Similar results have been sup-
ported in 2010 by a collaborative meta-analysis by Chronic
Kidney Disease Prognosis Consortium. Albumin/creatinine
(ACR) ratio was associated with risk of cardiovascular
mortality linearly without threshold effect. Compared with
ACR 0.6 mg/mmol, hazard ratio for cardiovascular mortality
were 1.27 for ACR 1.1 mg/mmol, 1.77 for 3.4 mg/mmol and
2.43 for 33.9 mg/mmol [39].
METABOLIC SYNDROME
According to Adult Treatment Panel III, the diagnosis of
MetS can be made whenever three or more of the following
parameters are met: triglycerides 150 mg/dl or more;
HDL cholesterol less than 40mg/dl for men and less than
50mg/dl for women; blood pressure 130/85 mmHg or
more; obesity as defined by a waist circumference 88 cm
or more for women and 102 cm or more for men; and
abnormal glucose metabolism as defined by a fasting glu-
cose 110 mg/dl or more [69].
The relationship between MetS, as defined by the WHO
[70–72], the IDF [70,73] and the ATPIII [69,72–80], and
cardiovascular events has been reported. In this regard,
analysis of large cohorts has proved that MetS is associated
with increased risk for coronary heart disease and stroke
[71,73,78,81], but recent studies failed to show superiority of
the MetS in predicting future CVD above and beyond its
single components, especially fasting glucose or hyper-
tension [70,82].
Several European [72,74,77] and American longitudinal
studies [75,76,79] explored the relation between MetS and
cardiovascular mortality, observing a 2.1-fold increase in
the risk of all-cause mortality and a 3.6 increase in cardi-
ovascular mortality, in patients free of CVD and diabetes
[72]. An association between the number of MetS criteria
and mortality from CVD has been also reported [79,83].
Even if MetS could be an independent risk factor for
mortality associated with a worse prognosis than its indi-
vidual components [76,83], Mancia et al. [74] recently
reported that increased risk for cardiovascular and all-cause
mortality in MetS patients was related only to blood pres-
sure and to blood glucose component of the syndrome,
with no contribution of the remaining components. Since
evidence about the ability of MetS to assess cardiovascular
risk is quite conflicting, its usefulness in predicting cardi-
ovascular mortality beyond risk chart is still largely debated.
A work from the Diabetes Epidemiology: Collaborative
analysis of Diagnostic Criteria in Europe study (the
DECODE study group 2006) supported a possible role of
MetS in detecting more patients at high risk of cardiovas-
cular death beyond those identified by SCORE. A total of
2790 middle-aged men without diabetes have beenorized reproduction of this article is prohibited.
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Cardiovascular risk assessment in presence
of subclinical organ damage
: Low risk at 10 years; : Intermediate risk at 10 years;
: Very high risk at 10 years;: High risk at 10 years;
LVH: left ventricular hypertrophy; MAU: microalbuminuria
LVH–
Score <5%
Score ≥5– <10%
Score ≥10– <20%
Score ≥20%
LVH+ MAU+MAU–
FIGURE 1 The reassessment of cardiovascular risk using indexes of target organ
damage in groups of patients with different Systemic Coronary Risk Estimation
(SCORE).
Volpe et al.followed for cardiovascular mortality recording over a
10-year follow-up. The main purpose was to determine
whether men at low risk (SCORE <5%) with MetS, as
defined by NCEP, had significantly higher cardiovascular
mortality than those without. Low-risk men with MetS had a
hazard ratio 2.26 (CI 95% 1.09–468) for the endpoint as
compared with men without MetS. In contrast, in the high-
risk population (SCORE 5%), hazard ratio for cardiovas-
cular death in presence of MetS was 1.08 (CI 95% 0.68–1.72,
NS). Most likely, in this, the later risk was mainly driven by
the classic cardiovascular risk factors. Furthermore, people
at low cardiovascular risk (SCORE<5%) with MetS have the
same cumulative hazards for cardiovascular death than
people at high risk (SCORE 5%) without MetS [84].
THE ADDITIONOF SUBCLINICALORGAN
DAMAGETO SYSTEMIC CORONARY RISK
ESTIMATION
Sehestedt et al. [85] investigated whether organ damage
could improve cardiovascular risk prediction beyond
SCORE. In an apparently healthy population, subclinical
organ damage as well as the number of damaged organs
was associated with increased cardiovascular risk, inde-
pendently of SCORE. However, combining risk models of
SCORE and subclinical organ damage yielded greater per-
formance on risk stratification and recommendation for
primary prevention. In particular, the presence of subclin-
ical organ damage in patients with SCORE 5% or more
identified a subgroup at particular high risk. Consequently,
restricting primary prevention to this group reduced the
number eligible for primary prevention by 20% and incre-
mented specificity compared with using SCORE alone. Of
note, measurement of subclinical organ damage in patients
with SCORE 5% or more could be used to identify patients
eligible for particular intensive primary prevention. Even in
individuals with SCORE less than 5%, the risk estimation
tended to be higher when organ damage was factored in. In
contrast, subclinical organ damage detection did not
improve cardiovascular risk prediction among patients with
SCORE less than 1%. On the basis of these findings, the
authors concluded that the most efficient approach would
be only to measure subclinical organ damage in patients
with SCORE between 1 and 5% rather than in those with
SCORE less than 1%.
Other studies have investigated the predictive value of
TOD on cardiovascular risk, showing, for instance, a strong
association of MAU in patients with hypertension. Leoncini
et al. [86], in a cross-sectional study, classified 58% of their
cohort in the high/very high added risk stratum according
to the 2007 ESH/ESC guidelines [3], by a simple routine
clinical workup. The simultaneous evaluation of urinary
albumin excretion and creatinine clearance resulted in a
significantly greater change in risk stratification, because
68% of the patients were reclassified in the high/very high
risk class. Viazzi et al. [87] reported that the combination of
albuminuria assessment and cardiovascular ultrasonogra-
phy greatly improved detection of target organ damage,
therefore allowing identification of a larger proportion of
patients at high risk as compared with those undergoing by
routine workup (73 vs. 42%) [86].Copyright © Lippincott Williams & Wilkins. Unaut
1060 www.jhypertension.comResults provided by Sehestedt et al. [85] allow reclassi-
fication of the cardiovascular risk as defined by SCORE by
simply adding LVH and MAU figures (Fig. 1). In patients
with a SCORE 5% or more, the cardiovascular risk would
actually be doubled, when taking into account the presence
of each these two markers of TOD. In patients with a
SCORE less than 5%, the presence of LVH almost doubles
the cardiovascular risk. Of note, the most relevant infor-
mation is reported by adding the evaluation of MAU to
SCORE in the subgroup of patients with a SCORE less than
5%. In fact, these patients in the presence of MAU would be
at high cardiovascular risk by having cardiovascular death
odds more than three-fold higher compared with those
without MAU. Although these initial observations are
encouraging, it should be pointed out that there are still
very few studies, particularly in the light of the heterogen-
eity of the risk populations.
LIMITATIONS
Our work has some possible limitations. For the purpose
our analysis, we selected from www.Pubmed.gov those
most relevant studies, including meta-analysis, published
between 2000 and 2011 about the cardiovascular prognos-
tic implications of the presence of TOD. We excluded small
investigations and substudies and did not use other search
database. As we searched the literature for studies with at
least 200 individuals, relevant small studies could have been
missed, partially biasing our search methodology. How-
ever, our literature search to support a viewpoint, based on
meta-analyses and the most representative and large stud-
ies, reflects overall a straightforward approach.
All the studies selected had different designs and
included nonhomogeneous population.
With regard to LVH, follow-up terms varied from one
study to another (from decades to months), some research-
ers did serial ECG and blood pressure analysis, whereas
others did not; only some excluded with an explicit state-
ment the possible influence of significant valvular defects
on LVH. At last, racial differences in assessing ECG criteria
for LVH have been reported, so the results derived in ahorized reproduction of this article is prohibited.
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racial groups.
With regard to renal damage, some studies evaluated
glomerular filtration rate by using MDRD formula, whereas
others used Cockcroft–Gault equation, some obtained
serial measurement of serum creatinine/UACR/MAU,
whereas others did not, leading to misclassification of
CKD status. Moreover, the prevalence of different degrees
of chronic kidney impairment across the population col-
lected varied from one study to another. Finally, in some
trials, the severity of comorbid medical conditions and
information on physical activity, tobacco/alcohol use were
not known.
MetS was defined using different definition (ATPIII-IDF-
WHO) across studies, possibly leading to misclassification
of the relationship with outcomes. However, this is a
common, generally accepted limit of most meta-analytical
studies on MetS.
In particular, in the study by Sehestedt et al., a small
number of events was recorded and it was not assessed
by an independent committee, also excluding diabetic
patients. This is different from the original SCORE dataset,
thus the SCORE could overestimate the risk in population of
Sehestedt et al..
CONCLUSION
The search of the best possible estimate of cardiovascular
risk in an individual patient represents a major need of
modern management of CVD and is at the same time a daily
clinical challenge for all physicians, specialists or general
practitioners. Risk charts are commonly used and referred
to as reliable way of cardiovascular risk stratification.
Nonetheless, they are not voided of pitfalls and weak-
nesses and the clinical yield is often not sufficient especi-
ally in patients with subclinical cardiorenal organ damage.
A better definition of the individual risk on a large-scale
population may in fact be achieved by evaluation of sub-
clinical organ damage by means of cost-effective tools that
can be used in primary prevention. The literature data
suggest that by diagnosing LVH and MAU, a reliable
reclassification of each patient is obtained. However, more
solid evidence is needed particularly in larger cohorts with
longer follow-up because there are still nonconclusive
prospective studies comparing different cardiovascular
risk assessment strategies with and without the inclusion
of parameters of target organ damage with sufficient fol-
low-up data.
More sophisticated and expensive markers of TOD have
also showed a predictive role in cardiovascular risk assess-
ment. For instance, carotid atherosclerosis, defined as
intima–media thickness or plaques, has been proven to
ameliorate the predictive ability of the Framingham risk
score [88], the SCORE [85] and the Progetto Cuore [89,90]
charts. Despite this, its usefulness in large-scale population
screening is actually limited by its elevated costs and high
dependence on operator and machine availability.
We can conclude that today there is much interest
and need to test the ability of new indexes of target
organ damage that are largely available, easy to obtain
and cheap.Copyright © Lippincott Williams & Wilkins. Unauth
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Reviewer 1
In their retrospective analysis Volpe and coworkers review
the additional predictive contribution of left ventricular
hypertrophy, eGFR, microalbuminuria, metabolic syn-
drome to standard cardiovascular risk assessment charts
such as Framingham or SCORE. The authors conclude that
there is some additional benefit of the above mentioned
parameters for the assessment of cardiovascular risk, as
compared to cardiovascular risk assessment by standard
risk charts. However, there is a large amount of evidence in
favour of better cardiovascular risk prediction when
parameters of target organ damage are measured. There-
fore conclusive prospective studies comparing different
cardiovascular risk assessment strategies with and withoutthe inclusion of parameters of target organ damage are
warranted.Reviewer 2
The strong point in the analysis by Volpe and coworkers
is that they only included studies with a large patient
group and that all had been published after the year
2000 so that the assessment of damage across the studies
was done with sound methods. A weak point, duly
acknowledged by the authors, is that outcome studies
varied markedly in duration of follow-up and sometimes
methodology. Also, the type of patients in the studies
varied substantially. Nevertheless, the paper provides a
good starting point for future prospective studies in this
area.horized reproduction of this article is prohibited.
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